National Institute on Drug Abuse, National Institutes of Health, Bethesda, Maryland.
JAMA Psychiatry. 2024 Mar 1;81(3):270-283. doi: 10.1001/jamapsychiatry.2023.4523.
Knowledge about characteristics of US pregnancy-associated decedents is needed to guide responses.
To examine individual sociodemographic characteristics and residing county's health care resources and socioeconomic factors among pregnancy-associated overdose decedents in comparison with obstetric decedents and overdose decedents who were not pregnant in the past year.
DESIGN, SETTING, AND PARTICIPANTS: This cross-sectional, exploratory study included 1457 pregnant and postpartum overdose decedents, 4796 obstetric decedents, and 11 205 nonpregnant overdose decedents aged 10 to 44 years from 2018 to 2021. Data were analyzed August 2023.
Decedents from the 2018-2021 Multiple Cause of Death Files linked to the 2021 Area Health Resources Files and the 2018-2021 County Health Rankings data at the county level.
Pregnancy-associated deaths were defined as deaths during pregnancy or within 1 year of pregnancy termination. This study focused on unintentional drug overdoses or drug overdoses with undetermined intent involving the most common psychotropic drugs of misuse.
From 2018 to 2021, across the pregnancy-postpartum continuum, pregnancy-associated overdose mortality ratios consistently increased among women aged 10 to 44 years. Mortality ratio more than tripled among pregnant and postpartum women aged 35 to 44 years from 4.9 (95% CI, 3.0-8.0) per 100 000 mothers aged 35 to 44 years with a live birth in January to June 2018 to 15.8 (95% CI, 12.3-20.4) in July to December 2021 (average semiannual percentage changes, 15.9; 95% CI, 8.7-23.6; P < .001). Compared with pregnant obstetric decedents, pregnant overdose decedents had increased odds of being aged 10 to 34 years (75.4% vs 59.5%; range of odds ratios [ORs], 1.8 [95% CI, 1.3-2.5] for ages 10 to 24 years to 2.2 [95% CI, 1.7-2.8] for ages 25 to 34 years), being non-college graduates (72.1% vs 59.4%; range of ORs, 2.7 [95% CI, 1.7-4.3] for those with some college education to 3.9 [95% CI, 2.4-6.1] for those with less than high school education), being unmarried (88.0% vs 62.1%; OR, 4.5; 95% CI, 3.7-6.0), and dying in nonhome, non-health care settings (25.9% vs 4.5%; OR, 2.5; 95% CI, 1.8-3.6) and were associated with decreased odds of dying in health care settings (34.7% vs 77.6%; range of ORs, 0.1 [95% CI, 0.1-0.1] for those who died in hospital inpatient settings to 0.4 [95% CI, 0.3-0.6] for those who died in hospital outpatient/emergency room settings).
From 2018 to 2021, the mortality ratio more than tripled among pregnant and postpartum women aged 35 to 44 years, consistent with increases in overdose mortality across US populations. Most pregnancy-associated overdose deaths occurred outside health care settings, indicating the need for strengthening community outreach and maternal medical support. To reduce pregnancy-associated overdose mortality, evidence-based interventions are urgently needed at individual, health care, local, and national levels, along with nonpunitive approaches incentivizing pregnant and postpartum women to seek substance use disorder treatments.
了解美国与妊娠相关的死亡者的特征对于指导应对措施至关重要。
与过去一年中没有怀孕的产科死亡者和过量用药死亡者相比,本研究旨在检查与妊娠相关的过量用药死亡者的个体社会人口统计学特征以及居住县的医疗保健资源和社会经济因素。
设计、设置和参与者:本横断面、探索性研究纳入了 2018 年至 2021 年期间来自多个死因文件的 1457 名妊娠和产后过量用药死亡者、4796 名产科死亡者和 11205 名过去一年中没有怀孕的过量用药死亡者,年龄在 10 至 44 岁之间。数据于 2023 年 8 月进行分析。
与 2021 年地区卫生资源文件和 2018 年至 2021 年县卫生排名数据相关联的 2018 年至 2021 年多原因死亡文件中的县一级数据。
妊娠相关死亡被定义为妊娠期间或妊娠终止后 1 年内的死亡。本研究主要关注非故意药物过量或涉及最常见的滥用精神药物的药物过量且意图不明的情况。
从 2018 年至 2021 年,在妊娠-产后连续体中,10 至 44 岁的妊娠和产后妇女的妊娠相关过量用药死亡率持续上升。35 至 44 岁的妊娠和产后妇女的死亡率比 2018 年 1 月至 6 月期间活产母亲中 35 至 44 岁年龄组的死亡率增加了两倍多,从每 100000 名母亲中 4.9(95%CI,3.0-8.0)增加到 2021 年 7 月至 12 月的 15.8(95%CI,12.3-20.4)(平均半年度百分比变化,15.9;95%CI,8.7-23.6;P<.001)。与妊娠产科死亡者相比,妊娠过量用药死亡者更有可能年龄在 10 至 34 岁(75.4%比 59.5%;比值比范围,1.8[95%CI,1.3-2.5]至 25 至 34 岁年龄组的 2.2[95%CI,1.7-2.8])、非大学毕业生(72.1%比 59.4%;比值比范围,具有一定大学教育程度的为 2.7[95%CI,1.7-4.3],具有低于高中学历的为 3.9[95%CI,2.4-6.1])、未婚(88.0%比 62.1%;比值,4.5;95%CI,3.7-6.0),并且更有可能在非家庭、非医疗保健场所死亡(25.9%比 4.5%;比值,2.5;95%CI,1.8-3.6),并且与在医疗保健场所死亡的可能性降低相关(34.7%比 77.6%;比值比范围,0.1[95%CI,0.1-0.1]至 0.4[95%CI,0.3-0.6]至在医院门诊/急诊室就诊的)。
从 2018 年至 2021 年,35 至 44 岁的妊娠和产后妇女的死亡率增加了两倍多,与全美人口的过量用药死亡率增加一致。大多数与妊娠相关的过量用药死亡发生在医疗保健场所之外,这表明需要加强社区外联和产妇医疗支持。为了降低与妊娠相关的过量用药死亡率,需要在个人、医疗保健、地方和国家各级采取基于证据的干预措施,并采取非惩罚性方法激励妊娠和产后妇女寻求物质使用障碍治疗。